Summary
The sparteine/debrisoquine oxidation polymorphism results from differences in the activity of one isozyme of cytochrome P450, the P450db1 (P450 IID1). The oxidation of more than 20 clinically useful drugs has now been shown to be under similar genetic control to that of sparteine/debrisoquine. The clinical significance of this polymorphism may be defined by the value of phenotyping patients before treatment. The clinical significance of such polymorphic elimination of a particular drug can be analyzed in three steps: first, does the kinetics of active principle of a drug depend significantly on P450db1?; second, is the resulting pharmacokinetic variability of any clinical importance?; and third, can the variation in response be assessed by direct clinical or paraclinical measurements? It is concluded from such an analysis that, in general, the sparteine/debrisoquine oxidation polymorphism is of significance in patient management only for those drugs for which plasma concentration measurements are considered useful and for which the elimination of the drug and/or its active metabolite is mainly determined by P450db1. At present, this applies to tricyclic antidepressants and to certain neuroleptics (e.g. perphenazine and thioridazine) and antiarrhythmics (e.g. propafenone and flecainide). Phenotyping should be introduced in to clinical routine under strictly controlled conditions to afford a better understanding of its potentials and limitations. The increasing knowledge of specific substrates and inhibitors of P450db1 allows precise predictions of drug-drug interactions. At present, the strong inhibitory effect of neuroleptics on the metabolism of tricyclic antidepressants represents the best clinically documented and most relevant example of such an interaction.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Alván G, Grind M, Graffner C, Sjöqvist F (1984) Relationship ofN-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism. Clin Pharmacol Ther 36: 515–519
Back DJ, Maggs JL, Purba HS, Newby S, Park BK (1984) 2-Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine. Br J Clin Pharmacol 18: 603–607
von Bahr C, Spina E, Birgersson C (1985) Inhibition of desmethylimipramine 2-hydroxolation by drugs in human liver microsomes. Biochem Pharmacol 14: 2501–2505
von Bahr C, Guengerich FP, Morin G, Nordin C (1989) The use of human liver banks in pharmacogenetic research. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry: From molecular studies to clinical reality. Springer, Berlin Heidelberg New York Tokyo (in press)
Balant LP, Gundert-Remy U, Boobis AR, von Bahr C (1989) Genetic polymorphism in drug metabolism: Relevance for the development of new drugs. Eur J Clin Pharmacol (in press)
Balant-Gorgia AE, Balant LP, Genet C, Dayer P, Aeschlimann JM, Garrone G (1986) Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 31: 449–455
Baumann P, Jonzier-Perey M, Koeb L, Küpfer A, Tinguely D, Schöpf J (1986) Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1: 102–112
Beckmann J, Hertrampf R, Gundert-Remy U, Mikus G, Gross AS, Eichelbaum M (1988) Is there a genetic factor in flecainide toxicity? Br Med J 297: 1316
Beerahee M, Wilkins MR, Jack DB, Beevers DG, Kendall MJ (1987) Twelve hour (through) plasma nifedipine concentrations during chronic treatment with nifedipine retard. Eur J Clin Pharmacol 32: 347–349
Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz H-U, Sjöqvist F (1980) Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 27: 1673–1677
Bertilsson L, Åberg-Wistedt A (1983) The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 15: 388–390
Bertilsson L, Åberg-Wistedt A, Gustafsson LL, Nordin C (1985) Extremely rapid hydroxylation of debrisoquine: A case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 7: 478–480
Bertilsson L, Henthorn TK, Sanch E, Tybring G, Säwe J, Villén T (1989) Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquine hydroxylation phenotype. Clin Pharmacol Ther (in press)
Boobis AR, Murray S, Kahn GC, Robertz GM, Davies DS (1983) Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol 23: 474–481
Brinn R, Brøsen K, Gram LF, Haghfelt T, Otton SV (1986) Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 22: 194–197
Brøsen K, Otton SV, Gram LF (1986a) Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 40: 543–549
Brøsen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L (1986b) Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 30: 679–684
Brøsen K, Gram LF, Haghfelt T, Bertilsson L (1987) Extensive metabolizers of debrisoquine become poor metabolizer during quinidine treatment. Pharmacol Toxicol 60: 312–314
Brøsen K, Gram LF (1988) First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 43: 400–406
Clark DWJ, Morgan AKW, Waal-Manning H (1984) Adverse effects from metoprolol are not generally associated with oxidation status. Br J Clin Pharmacol 18: 965–967
Cooper RG, Evans DAP, Price AH (1987) Studies on the metabolism of perhexiline in man. Eur J Clin Pharmacol 32: 569–576
Dahl SG (1986) Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokinet 11: 36–61
Dahl-Puustinen ML, Lidén A, Alm C, Bertilsson L (1989) Disposition of perphenazine is related to the polymorphic debrisoquine hydroxylation in man. Clin Pharmacol Ther (in press)
Dahlqvist R, Bertilsson L, Birkett DJ, Eichelbaum M, Säwe J, Sjöqvist F (1984) Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism. Clin Pharmacol Ther 35: 815–821
Danhof M, Idle JR, Teunissen MWE, Sloan TP, Breimer DD, Smith RL (1981) Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation. Pharmacology 22: 349–358
Dayer P, Balant L, Kupfer A, Striberni R, Leemann T (1985) Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. Eur J Clin PHarmacol 28: 317–320
Dayer P, Desmeules J, Leemann T, Striberni R (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 152: 411–416
Dayer P, Gasser R, Gut J, Kronbach T, Robertz GM, Eichelbaum M, Meyer UA (1984) Characterization of a common genetic defect of cytochrome P450 function (debrisoquine-sparteine type of polymorphism). Biochem Biophys Res Commun 125: 374–380
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979a) DefectiveN-oxidation of sparteine in man: A new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187
Eichelbaum M, Spannbrucker N, Dengler HJ (1979b) Influence of the defective metabolism of sparteine on its pharmacokinetics. Eur J Clin Pharmacol 16: 189–194
Eichelbaum M, Bertilsson L, Säwe J, Zekorn C (1982) Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities. Clin Pharmacol Ther 31: 184–186
Eichelbaum M, Tomson T, Tybring G, Bertilsson L (1985) Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokinet 10: 80–90
Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C (1986) The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 22: 49–53
Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105
Fonne-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cytochrome P-450db1 function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 37: 3829–3855
Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ (1987) Cloning of the cDNA for the human β1-adrenergic receptor. Proc Natl Acad Sci USA 84: 7920–7924
Gabris G, Baumann P, Jonzier-Perey M, Bosshart P, Woggon B, Küpfer A (1985) N-Methylation of maprotiline in debrisoquine/mephenytoin-phenotyped depressive patients. Biochem Pharmacol 34: 409–410
Gleiter CH, Aichele G, Nilsson E, Hengen N, Antonin KH, Bieck PR (1985) Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development. Br J Clin Pharmacol 20: 81–84
Gonzalez FJ, Skoda R, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331: 442–446
Gram LF (1975) Effects of perphenazine on imipramine metabolism in man. Psychopharmacol Commun 1: 165–175
Gram LF, Brøsen K (1989) Inhibitors of the microsomal oxidation of psychotropic drugs: Selectivity and clinical significance. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry: From molecular studies to clinical reality. Springer, Berlin Heidelberg New York Tokyo (in press)
Gram LF, Debruyne D, Caillard V, Boulenger JP, Lacotte J, Moulin M, Zarifian E (1989) Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 27: 272–275
Gram LF, Kragh-Sørensen P, Kristensen CB, Møller M, Pedersen OL, Thayssen P (1984) Plasma level monitoring of antidepressants: Theoretical basis and clinical application. In: Usdin E, Åsberg M, Bertilsson L, Sjöqvist F (eds) Frontiers in biochemical and pharmacological research in depression. Raven Press, New York, pp 399–411
Gram LF, Overø KF (1972) Drug interaction: Inhibitory of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 163: 463–465
Hirschowitz J, Bennet JA, Semian FP, Garber D (1983) Thioridazine effect on desipramine plasma levels. J Clin Psychopharmacol 3: 376–379
Inaba T, Jurima M, Mahon WA, Kalow W (1985) In vitro studies of two isozymes of human liver cytochrome P-450-mephenytoin hydroxylase and sparteine monooxygenase. Drug Metab Dispos 13: 443–448
Inaba T, Otton SV, Kalow W (1980) Deficient metabolism of sparteine and debrisoquine. Clin Pharmacol Ther 27: 547–549
Iyun AO, Lennard MS, Tucker GT, Woods HF (1986) Metoprolol and debrisoquin metabolism in Nigerians: Lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 40: 387–394
Jackson PR, Tucker GT, Lennard MS, Woods HF (1986) Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Pharmacol 22: 541–550
Kitchen I, Tremblay J, André, Dring LG, Idle JR, Smith RL, Williams RT (1979) Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 7: 397–404
Knodell RG, Raghvendra KD, Wilkinson GR, Guengerich FP (1988) Oxidative metabolism of hexobarbital in human liver: Relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther 245: 845–849
Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M (1989) In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 45: 28–33
Kronbach T, Fisher V, Meyer UA (1988) Cyclosporine metabolism in human liver: Identification of a cytochrome P450III gene family as the major cyclosporine metabolizing enzyme explaining interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43: 630–635
Küpfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753–759
Küpfer A, Branch RA (1985) Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther 38: 414–418
Leemann TP, Dayer P, Meyer UA (1986) Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 29: 739–741
Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF (1983) Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther 34: 732–737
Lennard MS, Jackson PR, Freestone S, Tucker GT, Ramsay LE, Woods HF (1984) The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol 17: 679–685
Lennard MS, McGourty JC, Silas JH (1988) Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin. Br J Clin Pharmacol 25: 276–278
Lewis RV, Lennard MS, Jackson PR, Tucker GT, Ramsay LE, Woods HF (1985) Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 19: 329–333
Lou YC, Ying L, Bertilsson L, Sjöqvist F (1987) Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 2: 852–853
Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586
Mellström B, Bertilsson L, Lou Y-C, Säwe J, Sjöqvist F (1983) Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 34: 516–520
Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, Catin T (1986) The molecular mechanisms of two common polymorphisms of drug oxidation — evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16: 449–464
Mikus G, Ha HR, Vozeh S, Zekorn F, Follath F, Eichelbaum M (1986) Pharmacokinetics and metabolism of quinidine in extensive and poor metabolizers of sparteine. Eur J Clin Pharmacol 31: 69–72
Miners JO, Wing LMH, Birkett DJ (1985) Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser. Austr NZ J Med 15: 348–349
Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402–408
Nebert DW, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gonsalus IC, Johnson EF, Kemper B, Levin W, Phillips IR, Sato R, Waterman MR (1987) The P450 gene super family: Recommended nomenclature. DNA 6: 1–11
Nordin C, Siwers B, Benitz J, Bertilsson L (1985) Plasma concentrations of nortriptyline and its 10-hydroxymetabolite in depressed patients-relationship to the debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol 19: 832–835
Oates NS, Shah RR, Idle JR, Smith RL (1983) Influence of oxidation polymophism on phenformin kinetics and dynamics. Clin Pharmacol Ther 34: 827–834
Oram M, Wilson K, Burnett D, Al-Dabbagh SG, Idle JR, Smith RL (1982) Metabolic oxidation of methaqualone in extensive and poor metabolizers of debrisoquine. Eur J Clin Pharmacol 23: 147–150
Otton SV, Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 34: 73–80
Pierce DM, Smith SE, Franklin RA (1987) The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. Eur J Clin Pharmacol 33: 59–65
Preskorn S (1989) Therapeutic drug monitoring of tricyclic antidepressants: A means of avoiding toxicity. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York Tokyo, in press
Roy SD, Hawes EM, McKay G, Korchinski ED, Midha KK (1985) Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin. Clin Pharmacol Ther 38: 128–133
Schmid B, Bircher J, Preisig R, Küpfer A (1985) Polymorphic dextromethorphan metabolism: Co-segretation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38: 618–624
Shaheen O, Patel J, Avant GR, Hamilton M, Wood AJJ (1986) Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil. Clin Pharmacol Ther 40: 650–655
Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Woosley RL (1987) Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75: 785–791
Siris SG, Cooper TB, Rifbein AE, Brenner R, Liebermann JA (1982) Plasma imipramine concentration in patients receiving concomitant fluphenazine decanoate. Am J Psychiatry 139: 104–106
Sjöqvist F, Bertilsson L (1986) Slow hydroxylation of tricylic anti-depressants — Relationship to polymorphic drug oxidation. In: Kalow W, Goedde HW, Agarwal DP (eds) Ethnic differences in reactions to drugs and xenobiotics. Alan R. Liss, New York, pp 169–188
Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL (1978) Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J 2: 655–657
Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL (1983) Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol 15: 443–450
Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS (1986) Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol 22: 739–743
Steiner E, Iselius L, Alván G, Lindsten J, Sjöqvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38: 394–401
Steiner E, Alván G, Garle M, Maguire JH, Lind M, Nilson S-O, Tomson T, McClanahan JS, Sjöqvist F (1987) The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin. Clin Pharmacol Ther 42: 326–333
Steiner E, Dumont E, Spina E, Dahlqvist R (1988a) Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther 43: 577–581
Steiner E, Bertilsson L, Säwe J, Bertling I, Sjöqvist F (1988b) Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44: 431–435
Syvählahti EKG, Lindberg R, Kallio J, de Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 22: 89–92
Wagner F, Kalusche D, Trenk D, Jänchen E, Roskamm H (1987a) Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol 24: 213–220
Wagner F, Jänchen E, Trenk D (1987b) Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem and sparteine. Klin Wochenschr 65: 1164–1168
Wang T, Roden DM, Wolfenden HT, Woosley RL, Wood AJJ, Wilkinson GR (1984) Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther 228: 605–611
Webb NR, Rose TM, Malik N, Marquardt H, Shoyab M, Todaro GJ, Lee DC (1987) Bovine and human cDNA sequences encoding a putative benzodiazepine receptor ligand. DNA 6: 71–79
Zanger UM, Vilbois F, Hardwick J, Meyer UA (1988) Absence of hepatic cytochrome P450buf I causes genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447–5454
Zekorn C, Achtert G, Hausleiter HJ, Moon CH, Eichelbaum M (1985) Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation. Klin Wochenschr 63: 1180–1186
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brøsen, K., Gram, L.F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36, 537–547 (1989). https://doi.org/10.1007/BF00637732
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00637732